Markets

Commodities

Currencies

ALX Oncology Announces Pricing of Underwritten Offering

New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology's Evorpacept in Combination with Ziihera in Advanced HER2-Positive Breast Cancer

ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference

loader